"Dinoprostone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The most common and most biologically active of the mammalian prostaglandins. It exhibits most biological activities characteristic of prostaglandins and has been used extensively as an oxytocic agent. The compound also displays a protective effect on the intestinal mucosa.
| Descriptor ID |
D015232
|
| MeSH Number(s) |
D10.251.355.255.550.250.200 D23.469.050.175.725.250.200
|
| Concept/Terms |
Dinoprostone- Dinoprostone
- PGE2 alpha
- alpha, PGE2
- Prostaglandin E2alpha
- E2alpha, Prostaglandin
- Prostaglandin E2
- E2, Prostaglandin
- Prostaglandin E2 alpha
- E2 alpha, Prostaglandin
- alpha, Prostaglandin E2
- PGE2
- PGE2alpha
|
Below are MeSH descriptors whose meaning is more general than "Dinoprostone".
Below are MeSH descriptors whose meaning is more specific than "Dinoprostone".
This graph shows the total number of publications written about "Dinoprostone" by people in this website by year, and whether "Dinoprostone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 1 | 1 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 4 | 4 |
| 2003 | 1 | 2 | 3 |
| 2004 | 1 | 3 | 4 |
| 2005 | 2 | 1 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 4 | 1 | 5 |
| 2008 | 0 | 2 | 2 |
| 2009 | 3 | 0 | 3 |
| 2010 | 1 | 2 | 3 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 0 | 1 | 1 |
| 2022 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dinoprostone" by people in Profiles.
-
Glutathione peroxidase 2 is a metabolic driver of the tumor immune microenvironment and immune checkpoint inhibitor response. J Immunother Cancer. 2022 08; 10(8).
-
Salivary Biomarker Evaluation of Chronic Pancreatitis Patients Reveals Alterations in Human Proteins, Cytokines, Prostaglandin E2 Levels, and Bacterial Diversity. Pancreas. 2022 08 01; 51(7):723-732.
-
Targeting EP2 receptor with multifaceted mechanisms for high-risk neuroblastoma. Cell Rep. 2022 06 21; 39(12):111000.
-
Inducible Prostaglandin E Synthase as a Pharmacological Target for Ischemic Stroke. Neurotherapeutics. 2022 01; 19(1):366-385.
-
Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death. Nat Commun. 2020 12 07; 11(1):6299.
-
EP2 Receptor Blockade Attenuates COX-2 Upregulation During Intestinal Inflammation. Shock. 2020 09; 54(3):394-401.
-
Acute changes in colonic PGE2 levels as a biomarker of efficacy after treatment of the Pirc (F344/NTac-Apc?am1137) rat with celecoxib. Inflamm Res. 2020 Jan; 69(1):131-137.
-
Sodium butyrate attenuates angiotensin II-induced cardiac hypertrophy by inhibiting COX2/PGE2 pathway via a HDAC5/HDAC6-dependent mechanism. J Cell Mol Med. 2019 12; 23(12):8139-8150.
-
TRPV4 Channel Signaling in Macrophages Promotes Gastrointestinal Motility via Direct Effects on Smooth Muscle Cells. Immunity. 2018 07 17; 49(1):107-119.e4.
-
The dual role of group V secretory phospholipase A2 in pancreatic ?-cells. Endocrine. 2017 Oct; 58(1):47-58.